Nanolek LLC, whose biotechnological production site is located in the Kirov Region (Orichevsky district, Levintsy), entered the list of systemically important organizations of the Russian economy.
The decision to include the organization in the list was taken by the Government Commission created to increase the sustainability of the development of the Russian economy. The industry list was published on the website of the Ministry of Industry and Trade of Russia on April 25, 2020.
The list of backbone organizations supervised by the Ministry of Industry and Trade of Russia includes organizations that meet the numerical criteria for the values of industry indicators established for industries also provides for some additional criteria. For pharmaceutical companies, there is a selection criterion - the revenue must be at least one billion rubles and the number of enterprises - at least 250. Let us remind you that the company’s revenue for 2019 amounted to 7.5 billion rubles, which is 60% higher than in 2018 (4.7 billion). The number of employees is more than 700 people.
“NANOLEK is a high-tech company that produces vaccines and socially significant medications for the treatment of HIV, cancer, orphan disorders, etc. All divisions: research, production, and logistics continue to operate without interruption, performing all contractual obligations. Moreover, in the middle of restrictive measures that were taken in connection with the COVID-19 pandemic, as well as instability of exchange rates, we need to count on support from the government”, said the company’s executive director Maxim Stetsyuk.
“Companies included in the list of backbone organizations have the right for the individual support and assistance with debt refinancing”, declared First Deputy Prime Minister Andrei Belousov.
About the Company
NANOLEK is a modern fast-growing Russian biopharmaceutical company with its high-tech full-cycle production according to the GMP and ISO standards, which specializes in the manufacture of import-substituting and innovative medicines, both of its design and created with the involvement of international partners, focusing on the prevention and treatment of socially significant diseases. The company has unique expertise in the field of technology transfer in partnerships with leading global pharmaceutical companies (e.g., Merck, Sanofi, Novartis, Egis, Celltrion, Riemser, etc..). Nanolek LLC took first place in the category “Fast-growing Large Companies” TEKHUSPEKH -2019 ranking. The company was also a member of Minek’s priority project “Support for Private High-Tech Leading Companies” (“National Champions”) in 2017.
Today, the company is one of the leaders in the production of pediatric vaccines in the Russian Federation. The diversified product portfolio of NANOLEK products is presented in the following therapeutic areas: vaccines, medications for the treatment of HIV, cancer, etc.
August 14, 2019, Nanolek LLC left the list of RUSNANO portfolio companies.